Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
At the extra general meeting of shareholders in AddLife AB (publ), reg. no. 556995-8126 ("AddLife") on 20 December 2018, it was resolved to approve the board of directors' resolution from 26 November 2018, to carry out an issue in kind and a preferential rights issue for existing shareholders in AddLife.
Kristina Willgård, CEO, informed about the background to the issue in kind, which is made to settle a part of the purchase price for the acquisition of Biomedica Medizinprodukte GmbH ("Biomedica"). She also informed about the background and purpose for the preferential rights issue, which is carried out to raise capital to continue to pursue AddLife's growth strategy and to carry out more strategic acquisitions.
The total number of B-shares that the sellers of shares in Biomedica has the right to subscribe for amounts to 480,721, which means an increase of the share capital with SEK 979,246.89. The subscription price has been set to approximately EUR 20.3. The sellers has undertaken not to sell, transfer, pledge or otherwise dispose of their shares in AddLife during a period of 24 month after the acquisition of Biomedica.
The complete terms of the rights issue, including the increase of the share capital, number of shares to be issued and subscription price are expected to be announced at the latest on 23 January 2019. The record date for the preferential rights issue shall be 30 January 2019 and the subscription period is expected to be during the period from 1 February 2019 up to and including 15 February 2019.
For more information on the issue in kind and the preferential right issue, please refer to previous press releases from the company published on 26 November 2018.
Stockholm 20 December 2018
AddLife AB (publ)
For further information, please contact:
Kristina Willgård, CEO, kristina.willgard@add.life,+46 (0)705 10 12 23
Martin Almgren, CFO, martin.almgren@add.life,+46 (0)702 28 15 45
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW.
AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region. AddLife has about 600 employees in some 30 operating subsidiaries. The group currently has net sales of around SEK 2.5 billion. The AddLife share is listed on NASDAQ Stockholm.
The information in this press release is of the nature that AddLife AB (publ) is obliged to make public pursuant to Nasdaq Stockholm rulebook for issuers. The information was submitted for publication, through the agency of the contact persons set out above, at 20 December 2018 At 12 PM (CET).